Human immunodeficiency virus downregulates podocyte apoE expression

American Journal of Physiology - Renal Physiology

Volumn 297, Issue 3, 2009, Pages

  Arora, Shitij ^a   Husain, Mohammad ^a   Kumar, Dileep ^a   Patni, Hitesh ^a   Pathak, Shresh ^a   Mehrotra, Devi ^a   Reddy, Vivek Kathi ^a   Reddy, Lalit Rajeev ^a   Salhan, Divya ^a   Yadav, Anju ^a   Mathieson, Peter W ^b   Saleem, Moin A ^b   Chander, Praveen N ^c   Singhal, Pravin C ^a,d  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c NEW YORK MEDICAL COLLEGE   (United States)

^d Div of Kidney Diseases and Hypertension   (United States)

Author keywords

Apolipoprotein E; Mesangial cells; Pelecan

Indexed keywords

APOLIPOPROTEIN E; GAG PROTEIN; HEPARAN SULFATE; MESSENGER RNA; NEF PROTEIN; PERLECAN; POL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL IMMORTALIZATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE CONSTRUCT; GENE FUNCTION; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY PARENCHYMA; MALE; MESANGIUM CELL; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE;

EID: 69449089082     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.90668.2008     Document Type: Article

References (47)

1. Bourgoignie JJ, Pardo V. The nephropathology in human immunodeficiency virus (HIV-1) infection. Kidney Int 40, Suppl: S19-S23, 1991.
2. Briz V, Poveda E, Soriano V. HIV entry inhibitors: mechanisms of action and resistance pathways. J Antimicrob Chemother 57: 619-627, 2006.
3. Bruneval P, Bariéty J, Bélair MF, Mandet C, Heudes D, Nicoletti A. Mesangial expansion associated with glomerular endothelial cell activation and macrophage recruitment is developing in hyperlipidaemic apoE null mice. Nephrol Dial Transplant 17: 2099-2107, 2002. (Pubitemid 35446664)
4. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci USA 105: 8718-8723, 2008. (Pubitemid 351987746)
5. Campbell SM, Crowe SM, Mak J. Lipid rafts and HIV-1: from viral entry to assembly of progeny virions. J Clin Virol 22: 217-227, 2001. (Pubitemid 32846552)
6. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S. A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 276: 49142-49147, 2001. (Pubitemid 37370621)
7. Chen Q, Sivakumar P, Barley C, Peters DM, Gomes RR, Farach-Carson MC, Dallas SL. Potential role for heparan sulfate proteoglycans in regulation of transforming growth factor-beta (TGF-beta) by modulating assembly of latent TGF-beta-binding protein. J Biol Chem 282: 26418-26430, 2007. (Pubitemid 47443781)
8. Chertova E, Chertova O, Coren LV, Roser JD, Trubey CM, Bess JW Jr, Sowder RC 2nd, Barsov E, Hood BL, Fisher RJ, Nagashima K, Conrads TP, Veenstra TD, Lifson JD, Ott DE. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. J Virol 80: 9039-9052, 2006.
9. Conde-Knape K. Heparan sulfate proteoglycans in experimental models of diabetes: a role for perlecan in diabetes complications. Diabetes Metab Res Rev 17: 412-421, 2001. (Pubitemid 34030743)
10. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923, 1993. (Pubitemid 23275809)
11. Dickie P, Roberts A, Uwiera R, Witmer J, Sharma K, Kopp JB. Focal glomerulosclerosis in proviral and c-fms transgenic mice links Vpr expression to HIV-associated nephropathy. Virology 322: 69-81, 2004. (Pubitemid 38519870)
12. Dobson CB, Sales SD, Hoggard P, Wozniak MA, Crutcher KA. The receptor-binding region of human apolipoprotein E has direct anti-infective activity. J Infect Dis 193: 442-450, 2006. (Pubitemid 43122345)
13. Gambaro G, Kinalska I, Oksa A, Pont'uch P, Hertlová M, Olsovsky J, Manitius J, Fedele D, Czekalski S, Perusicová J, Skrha J, Taton J, Grzeszczak W, Crepaldi G. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. randomized trial. J Am Soc Nephrol 13: 1615-1625, 2002.
14. Heerspink HL, Greene T, Lewis JB, Raz I, Rohde RD, Hunsicker LG, Schwartz SL, Aronoff S, Katz MA, Eisner GM, Mersey JH, Wiegmann TB, Collaborative Study Group. Effects of sulodexide in patients with type 2 diabetes and persistent albuminuria. Nephrol Dial Transplant 23: 1946-1954, 2008.
15. Husain M, D'Agati VD, He JC, Klotman ME, Klotman PE. HIV-1 Nef induces dedifferentiation of podocytes in vivo: a characteristic feature of HIVAN. AIDS 19: 1975-1980, 2005.
16. Husain M, Gusella GL, Klotman ME, Gelman IH, Ross MD, Schwartz EJ, Cara A, Klotman PE. HIV-1 Nef induces proliferation and anchorage-independent growth in podocytes. J Am Soc Nephrol 13: 1806-1815, 2002.
17. Jacobson DL, Tang AM, Spiegelman D, Thomas AM, Skinner S, Gorbach SL, Wanke C. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Survey). J Acquir Immune Defic Syndr Hum Retrovirol 43: 458-466, 2006. (Pubitemid 44737105)
18. Kelly BA, Neil SJ, McKnight A, Santos JM, Sinnis P, Jack ER, Middleton DA, Dobson CB. Apolipoprotein E-derived antimicrobial peptide analogues with altered membrane affinity and increased potency and breadth of activity. FEBS J 274: 4511-4525, 2007. (Pubitemid 47301713)
19. Kopp JB, Klotman ME, Adler SH, Bruggeman LA, Dickie P, Marinos NJ, Eckhaus M, Bryant JL, Notkins AL, Klotman PE. Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 89: 1577-1581, 1992.
20. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 240: 622-630, 1988.
21. Mahley RW, Ji ZS. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40: 1-16, 1999.
22. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet 1: 507-537, 2000.
23. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA 103: 5644-5651, 2006.
24. Martin I, Dubois MC, Saermark T, Ruysschaert JM. Apolipoprotein A-1 interacts with the N-terminal fusogenic domains of SIV (simian immunodeficiency virus) GP32 and HIV (human immunodeficiency virus) GP41: implications in viral entry. Biochem Biophys Res Commun 186: 95-101, 1992.
25. McCune JM, Rabin LB, Feinberg MB, Lieberman M, Kosek JC, Reyes GR, Weissman IL. Endoproteolytic cleavage of gp160 is required for the activation of human immunodeficiency virus. Cell 53: 55-67, 1988. (Pubitemid 18104049)
26. Moeller MJ, Sanden SK, Soofi A, Wiggins RC, Holzman LB. Podocyte- specific expression of cre recombinase in transgenic mice. Genesis 35: 39-42, 2003. (Pubitemid 36150980)
27. Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K. Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population. Clin Infect Dis 44: 726-734, 2007. (Pubitemid 46272986)
28. Monsuez JJ, Escaut L, Teicher E, Charniot JC, Vittecoq D. Cytokines in HIV associated cardiomyopathy. Int J Cardiol 120: 150-157, 2007.
29. Moretti EW, Morris RW, Podgoreanu M, Schwinn DA, Newman MF, Bennett E, Moulin VG, Mba UU, Laskowitz DT, Perioperative Genetics, and Safety Outcomes Study (PEGASUS) Investigative Team. APOE polymorphism is associated with risk of severe sepsis in surgical patients. Crit Care Med 33: 2521-2526, 2005. (Pubitemid 41682104)
30. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D. Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 11: e365, 2006. (Pubitemid 44646310)
31. Nakashima Y, Fujii H, Sumiyoshi S, Wight TN, Sueishi K. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol 27: 1159-1165, 2007. (Pubitemid 46641972)
32. Nakashima Y, Plump AS, Raines EW, Breslow JL, Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 42: 943-950, 1994. (Pubitemid 24028177)
33. Nguyen DH, Hildreth JE. Evidence for budding of human immunode- ficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol 74: 3264-3272, 2000.
34. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci USA 98: 13925-13930, 2001. (Pubitemid 33116000)
35. Owens BJ, Anantharamaiah GM, Kahlon JB, Srinivas RV, Compans RW, Segrest JP. Apolipoprotein A-I and its amphipathic helix peptide analogues inhibit human immunodeficiency virus-induced syncytium formation. J Clin Invest 86: 1142-1150, 1990.
36. Pardo V, Aldana M, Colton RM, Fischl MA, Jaffe D, Moskowitz L, Hensley GT, Bourgoignie JJ. Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101: 429-434, 1984. (Pubitemid 14018035)
37. Raats CJ, Luca ME, Bakker MA, Van Der Wal A, Heeringa P, Van Goor H, Van Den Born J, De Heer E, Berden JH. Reduction in glomerular heparan sulfate correlates with complement deposition and albuminuria in active Heymann nephritis. J Am Soc Nephrol 10: 1689-1699, 1999. (Pubitemid 29364667)
38. Saleem MA, O'Hare MJ, Reiser J, Coward RJ, Inward CD, Farren T, Xing CY, Ni L, Mathieson PW, Mundel P. A conditionally immortalized human podocyte cell line demonstrating nephrin and podocin expression. J Am Soc Nephrol 133: 630-638, 2002. (Pubitemid 34183927)
39. Singh IP, Chopra AK, Coppenhaver DH, Ananatharamaiah GM, Baron S. Lipoproteins account for part of the broad non-specific antiviral activity of human serum. Antiviral Res 42: 211-218, 1999. (Pubitemid 29335908)
40. Smith JD. Apolipoprotein E4: an allele associated with many diseases. Ann Med 32: 118-127, 2000.
41. van Det NF, van den Born J, Tamsma JT, Verhagen NA, van den Heuvel LP, Berden JH, Bruijn JA, Daha MR, van der Woude FJ. Proteoglycan production by human glomerular visceral epithelial cells and mesangial cells in vitro. Biochem J 307: 759-768, 1995.
42. Weisgraber KH. Apolipoprotein E: structure-function relationships. Adv Protein Chem 45: 249-302, 1994.
43. Wen M, Segerer S, Dantas M, Brown PA, Hudkins KL, Goodpaster T, Kirk E, LeBoeuf RC, Alpers CE. Renal injury in apolipoprotein E-deficient mice. Lab Invest 82: 999-1006, 2002. (Pubitemid 34894348)
44. Yang Y, Zhang SY, Sich M, Béziau A, van den Heuvel LP, Gubler MC. Glomerular extracellular matrix and growth factors in diffuse mesangial sclerosis. Pediatr Nephrol 16: 429-438, 2001. (Pubitemid 32447708)
45. Zhang S, Reddick R, Piedrahita J, Maeda N. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258: 468-471, 1992.
46. Zhou H, Pandak WM Jr, Lyall V, Natarajan R, Hylemon PB. HIV protease inhibitors activate the unfolded protein response in macrophages: implication for atherosclerosis and cardiovascular disease. Mol Pharmacol 68: 690-700, 2005. (Pubitemid 41206022)
47. Zuo Y, Matsusaka T, Zhong J, Ma J, Ma LJ, Hanna Z, Jolicoeur P, Fogo AB, Ichikawa I. HIV-1 genes vpr and nef synergistically damage podocytes, leading to glomerulosclerosis. J Am Soc Nephrol 17: 2832-2843, 2006. (Pubitemid 44484673)